Evidence map›Paper›PMID 32065361›Full record

ArticleHuman cell2020

Long non-coding RNA NEAT1 promotes colorectal cancer progression by regulating miR-205-5p/VEGFA axis.

Huijie Liu, Aiyi Li, Zhichao Sun, Jingyu Zhang, Hua Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Functional, Pharmacogenomic, and Immune Landscapes of Long Non-Coding RNAs in Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Article
  6. Review
  7. Tumor-exosomal miR-205-5p as a diagnostic biomarker for colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  8. Article
  9. Exploring the Key Signaling Pathways and ncRNAs in Colorectal Cancer.International journal of molecular sciences · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Recent advances of NEAT1-miRNA interactions in cancer.Acta biochimica et biophysica Sinica · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Huijie Liu *Department of Breast Oncology, Xiang Yang Central Hospital, The Affiliated Hospital of Hubei College of Arts and Sciences, 136 Jingzhou Street, Xiangyang, 441021, Hubei, China.
Aiyi Li *Disinfection Supply Center, The Second People's Hospital of Lianyungang, Lianyungang, 222023, China.
Zhichao SunDepartment of Pathology, The Second People's Hospital of Lianyungang, Lianyungang, 222023, China.
Jingyu ZhangDepartment of Tumor-Chemotherapy, The Second People's Hospital of Lianyungang, 161 Xingfu Road, Haizhou, Lianyungang, 222023, Jiangsu, China. njdhw123@163.com.
Hua XuDepartment of Breast Oncology, Xiang Yang Central Hospital, The Affiliated Hospital of Hubei College of Arts and Sciences, 136 Jingzhou Street, Xiangyang, 441021, Hubei, China. xuhua8890@163.com.
The First People’s Hospital of Lianyungang · CNXiangyang Central Hospital · CNXian Yang Central Hospital · CN

Funding

Jiangsu University Medical Clinical Science and Technology Development Fund Project JLY20140133
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) play key roles in tumorigenesis. It has been reported that the lncRNA nuclear-enriched abundant transcript 1 (NEAT1) may act as an oncogenic regulator in several cancers. However, the biological mechanism of action of NEAT1, particularly the miRNA sponge role in colorectal cancer (CRC), has not been fully elucidated. In our study, the expression of NEAT1, miR-205-5p, and vascular endothelial growth factor A (VEGFA) in CRC cell lines were assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Cell proliferation was detected by Cell Counting Kit-8 (CCK-8) assay. Cell migration and invasion were examined by wound healing and transwell assays, respectively. RNA-binding protein immunoprecipitation (RIP), and dual-luciferase and RNA pull-down assays were conducted to determine the correlation between miR-205-5p and NEAT1 or VEGFA. VEGFA, matrix metalloproteinase (MMP)2, and MMP9 protein and mRNA expression were measured by western blotting and RT-qPCR analysis, respectively. Our results demonstrated high expression of NEAT1 and VEGFA and low expression of miR-205-5p in CRC cell lines. The RIP and dual-luciferase assays confirmed miR-205-5p as a target of NEAT1. In addition, VEGFA was identified as a direct target of miR-205-5p. Inhibition of NEAT1 or overexpression of miR-205-5p was able to repress VEGFA expression. Moreover, downregulation of NEAT1 and VEGFA inhibited cell proliferation, migration, and invasion. NEAT1 overexpression facilitated tumor growth by modulating miR-205-5p. Taken together, lncRNA NEAT1 was found to be upregulated in CRC cell lines, promoting CRC cell proliferation, migration, and invasion through regulating the miR-205-5p/VEGFA signaling pathway. These findings suggest that NEAT1 may be a promising biomarker in CRC diagnosis and treatment.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorColorectal NeoplasmsDisease ProgressionHumansMicroRNAsRNA, Long NoncodingVascular Endothelial Growth Factor ABiomarkers, TumorMicroRNAsMIR205, humanNEAT1 long non-coding RNA, humanRNA, Long NoncodingVascular Endothelial Growth Factor AVEGFA protein, humanColorectal cancerInvasionLncRNA NEAT1MigrationmiR-205-5pProliferationVEGFA

Identifiers

PMID32065361
OpenAlexW3005639993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.